Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.78M fell 2.4% year over year, behind the +29.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +94.1% a year.
Context
- Depreciation & amortization amounted to 14.1% of revenue in FY2025, up 2.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +29.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 7.23M USD
- Year-over-year change
- +80.0%
- 4-year CAGR
- +79.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.23M | +80.0% |
| FY2024 | 2024-12-31 | 4.02M | +227.4% |
| FY2023 | 2023-12-31 | 1.23M | +24.1% |
| FY2022 | 2022-12-31 | 989K | +41.1% |
| FY2021 | 2021-12-31 | 701K | — |
Depreciation & Amortization vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +29.5% is the 2nd highest of 8, against a peer median of +2.0%.
- Depreciation & amortization amounts to 14.1% of revenue for CPH.TO, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$61.18M CAD | +17.4% | -3.3% | 12.0% | |
| LTM Mar 2026 | CA$40.12M CAD | -6.9% | -23.0% | 12.9% | |
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | $16.18M USD | -28.9% | -10.7% | 6.2% | |
| LTM Mar 2026 | CA$13.39M CAD | -40.6% | -31.2% | 4.2% | |
| LTM Mar 2026 | $7.19M USD | +29.5% | +94.1% | 14.1% | |
| LTM Mar 2026 | CA$253K CAD | +2.0% | -2.8% | 9.2% | |
| LTM Mar 2026 | $128K USD | +24.3% | -11.6% | 0.3% | |
| Peer median (excluding CPH.TO) | — | +2.0% | -11.2% | 7.2% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.94M | 20.68M | 21.16M | 33.36M | 51.33M |
| Cost of Revenue | 3.68M | 3.99M | 4.07M | 9.26M | 17.56M |
| Gross Profit | 18.26M | 16.68M | 17.09M | 24.1M | 33.77M |
| Gross Margin | 83.2% | 80.7% | 80.8% | 72.2% | 65.8% |
| Research & Development | 88K | 98K | 139K | 0 | 21.37K |
| Selling, General & Admin | 5.11M | 4.4M | 5.43M | 12.24M | 16.3M |
| Operating Expenses | 6.45M | 5.63M | 5.56M | 16.26M | 16.97M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| EBITDA | 13.66M | 12.04M | 11.53M | 11.87M | 24.1M |
| EBITDA Margin | 62.2% | 58.2% | 54.5% | 35.6% | 46.9% |
| Operating Income | 11.82M | 12.04M | 11.53M | 7.85M | 16.8M |
| Operating Margin | 53.9% | 58.2% | 54.5% | 23.5% | 32.7% |
| Interest Income | 12K | 464K | 1.87M | 330K | 0 |
| Interest Expense | 92K | 0 | 0 | 0 | 1.19M |
| Other Income / Expenses | (2M) | (560K) | 1.15M | (4.89M) | 661.38K |
| Income Before Tax | 11.06M | 11.48M | 12.68M | 2.96M | 17.46M |
| Pre-Tax Margin | 50.4% | 55.5% | 59.9% | 8.9% | 34.0% |
| Income Tax Expense | 3.3M | (15.16M) | (7.7M) | (8.59M) | (10.34M) |
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.81M |
| Net Margin | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% |
| EPS (Basic) | 0.29 | 1.06 | 0.80 | 0.47 | 1.09 |
| EPS (Diluted) | 0.29 | 1.04 | 0.80 | 0.47 | 1.07 |
| Weighted Avg Shares | 26.6M | 25.13M | 25.48M | 24.72M | 25.48M |
| Weighted Avg Shares (Diluted) | 26.83M | 25.59M | 25.42M | 24.57M | 25.99M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.